Jiva Pharma, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 12, 2027The maintenance fee for 5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents (US 10,646,477) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,808,497 | Formulations of concentrated prunes and prebiotics as laxatives and dietary supplements In force · From the USPTO record | In force | From the USPTO record | |
| US 9,364,465 | Thiazolidinediones of omega-3 polyunsaturated acids as new insulin sensitizers for treating type2 diabetes In force · From the USPTO record | In force | From the USPTO record | |
| US 9,815,777 | Metformin salts to treat Type2 diabetes In force · From the USPTO record | In force | From the USPTO record | |
| US 9,540,307 | Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia In force · From the USPTO record | In force | From the USPTO record | |
| US 9,688,613 | Omegabalins, GABA derivatives of omega-3 polyunsaturated acids, their formulations and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,646,477 | 5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents In force · From the USPTO record | In force | From the USPTO record | |
| US 11,202,774 | 5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents In force · From the USPTO record | In force | From the USPTO record | |
| US 10,125,078 | NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 no status recorded